Innoviva Total Assets 2012-2026 | INVA
Innoviva total assets from 2012 to 2026. Total assets can be defined as the sum of all assets on a company's balance sheet.
|
Innoviva Annual Total Assets (Millions of US $) |
|
|---|---|
| 2025 | $1,635 |
| 2024 | $1,301 |
| 2023 | $1,244 |
| 2022 | $1,231 |
| 2021 | $926 |
| 2020 | $1,000 |
| 2019 | $725 |
| 2018 | $548 |
| 2017 | $367 |
| 2016 | $379 |
| 2015 | $409 |
| 2014 | $522 |
| 2013 | $681 |
| 2012 | $369 |
| 2011 | $259 |
|
Innoviva Quarterly Total Assets (Millions of US $) |
|
|---|---|
| 2026-03-31 | $1,837 |
| 2025-09-30 | $1,429 |
| 2025-06-30 | $1,334 |
| 2025-03-31 | $1,254 |
| 2024-12-31 | $1,301 |
| 2024-09-30 | $1,232 |
| 2024-06-30 | $1,225 |
| 2024-03-31 | $1,268 |
| 2023-12-31 | $1,244 |
| 2023-09-30 | $1,188 |
| 2023-06-30 | $1,118 |
| 2023-03-31 | $1,130 |
| 2022-12-31 | $1,231 |
| 2022-09-30 | $1,328 |
| 2022-06-30 | $1,138 |
| 2022-03-31 | $1,107 |
| 2021-12-31 | $926 |
| 2021-09-30 | $887 |
| 2021-06-30 | $789 |
| 2021-03-31 | $1,088 |
| 2020-12-31 | $1,000 |
| 2020-09-30 | $922 |
| 2020-06-30 | $880 |
| 2020-03-31 | $788 |
| 2019-12-31 | $725 |
| 2019-09-30 | $676 |
| 2019-06-30 | $642 |
| 2019-03-31 | $590 |
| 2018-12-31 | $548 |
| 2018-09-30 | $278 |
| 2018-06-30 | $339 |
| 2018-03-31 | $277 |
| 2017-12-31 | $367 |
| 2017-09-30 | $391 |
| 2017-06-30 | $372 |
| 2017-03-31 | $392 |
| 2016-12-31 | $379 |
| 2016-09-30 | $371 |
| 2016-06-30 | $378 |
| 2016-03-31 | $388 |
| 2015-12-31 | $409 |
| 2015-09-30 | $438 |
| 2015-06-30 | $462 |
| 2015-03-31 | $489 |
| 2014-12-31 | $522 |
| 2014-09-30 | $554 |
| 2014-06-30 | $606 |
| 2014-03-31 | $605 |
| 2013-12-31 | $681 |
| 2013-09-30 | $666 |
| 2013-06-30 | $595 |
| 2013-03-31 | $592 |
| 2012-12-31 | $369 |
| 2012-09-30 | $384 |
| 2012-06-30 | $399 |
| 2012-03-31 | $218 |
| 2011-12-31 | $259 |
| 2011-09-30 | $283 |
| 2011-06-30 | $303 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |